Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12011089 | 0.73 | HRH3 (0.58) | MEN1ALDH1A1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL25754765 | 0.73 | MAPT (0.37) | GAAALDH1A1IKBKBCHUKLMNA | |
| SCHEMBL13870642 | 0.68 | NAMPT (0.53) | NAMPTKMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL18381385 | 0.68 | LMNA (0.47) | LMNASMN1; SMN2 | |
| SCHEMBL29460411 | 0.66 | MCL1 (0.39) | GAAALDH1A1LMNA | |
| SCHEMBL19151079 | 0.65 | NAMPT (0.50) | NAMPTMEN1KMT2ALMNA | |
| SCHEMBL6959928 | 0.64 | NAMPT (0.40) | NAMPTGAAMEN1ALDH1A1KMT2A | |
| SCHEMBL9906891 | 0.64 | QPCT (0.59) | MEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL13949577 | 0.63 | — | — | |
| SCHEMBL25755309 | 0.63 | GAA (0.33) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | NAMPT 3233/4885GAA 520/4885MEN1 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.